Company: BWXT
Filing Date: 2025-03-19
Form Type: 10-K/A
Source: 0001486957-25-000015
Chunk: 73

Company: BWX Technologies, Inc.
Filing Date: 2025-03-19
Form: 10-K/A
Chunk 73
---
     | $       |      — |
| Interest payments        |     | $              |   203,199 |     | $         | 58,439 |     | $     | 111,760 |     | $     |  33,000 |     | $       |      — |
| Lease payments           |     | $              |    30,090 |     | $         |  3,930 |     | $     |   5,600 |     | $     |   4,318 |     | $       | 16,242 |

Our contingent commitments under letters of credit and surety bonds currently outstanding expire as follows:

| Total          |     | Less than 
    1 Year |     |      1-3 
    Years |     |       3-5 
     Years |     | Thereafter |
| (In thousands) |     |           |     |          |     |           |     |            |
| $ 313,671      |     | $ 133,100 |     | $ 30,192 |     | $ 150,380 |     | $ —        |

Other cash requirements include, among other things, capital expenditures, payment of dividends, repurchases of common stock, capital contributions for joint ventures and contributions to our pension and other postretirement benefit plans.

Since 2017, we have made considerable investments in property, plant and equipment to support the growth of our Government Operations and Commercial Operations segments. Significant projects included the expansion of Government Operations facilities to support increased demand from the U.S. Government and the commercialization of our medical radioisotope technology in our Commercial Operations segment. We expect these heightened spending levels to decline as these capital expansion projects are largely complete.

During the year ended December 31, 2024, we paid $88.3 million in dividends to holders of our common stock. The declaration and payment of future dividends will be at the discretion of our Board of Directors and will depend upon many factors, including our financial condition, earnings, capital requirements of our business, legal and regulatory requirements and other factors that our Board of Directors may deem relevant.

In April 2021, our Board of Directors authorized us to repurchase an indeterminate number of shares of our common stock up to an aggregate market value of $500 million. As of December 31, 2024, the total remaining share repurchase authorization was $377.6 million. See Item 5 of this Report for additional